Latest Commercialization News

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.

Green Critical Minerals has secured a formal sample request from a leading European thermal management provider, marking a significant step in commercialising its VHD Graphite technology across multiple high-demand sectors.

Patagonia Lithium Ltd reports exceptional Nuclear Magnetic Resonance (NMR) porosity and specific yield results from well JAM24-04 at its Formentera Lithium Brine Project in Argentina, revealing porosity values more than double previous estimates and promising lithium concentrations that bolster project viability.

Barton Gold Holdings has released an Optimised Scoping Study for its Tunkillia Gold Project, revealing significant improvements in project economics, including a sub-one-year payback and reduced capital expenditure. The study paves the way for accelerated feasibility work and funding efforts.

Reliance Worldwide Corporation outlines its strategic response to US tariffs, emphasizing diversified sourcing and price adjustments to sustain margins in a $25.3 billion plumbing market. The company forecasts broadly flat FY25 sales with slight margin pressure but remains confident in long-term growth.

New World Resources has announced a significant 25% increase in the Antler Copper Project's mineral resource, enhancing geological confidence and contained metals, setting a robust stage for production targeted in 2027.

Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.

Westpac Banking Corporation posted a $3.5 billion net profit for the first half of 2025, maintaining strong capital ratios and advancing its digital transformation and sustainability initiatives despite a slight earnings dip.

Zoono Group Limited has responded to an ASX price query following unusual trading activity, confirming no undisclosed price-sensitive information exists and linking the movement to ongoing shelf-life extension trials with OSY Group Ltd and multiple international partners.

Anagenics Limited has completed a significant restructuring to simplify operations and issued 35 million shares to FOS Capital as part of this process. The company confirms its going concern status and outlines plans for organic and acquisitive growth over the next year.

Opyl Limited has successfully raised $1.5 million through an oversubscribed placement to accelerate the growth of its AI-driven clinical trial platform, Trialkey. The capital injection underscores strong investor confidence as the company prepares for a pivotal expansion phase.